Nutraceuticals
搜索文档
Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026
Globenewswire· 2025-11-05 06:01
Sales of $478 million, down eight percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. Excluding these initiatives, sales declined one percentIncome from continuing operations of $33 million, or $0.73 per diluted shareAdjusted Income from Continuing Operati ...